ArticleJournal of the American Statistical Association2021
Rejoinder: Learning Optimal Distributionally Robust Individualized Treatment Rules.
Article in Journal of the American Statistical Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We thank the opportunity offered by editors for this discussion and the discussants for their insightful comments and thoughtful contributions. We also want to congratulate Kallus (2020) for his inspiring work in improving the effciency of policy learning by retargeting. Motivated from the discussion in Dukes and Vansteelandt (2020), we first point out interesting connections and distinctions between our work and Kallus (2020) in Section 1. In particular, the assumptions and sources of variation for consideration in these two papers lead to different research problems with different scopes and focuses. In Section 2, following the discussions in Li et al. (2020); Liang and Zhao (2020), we also consider the efficient policy evaluation problem when we have some data from the testing distribution available at the training stage. We show that under the assumption that the sample sizes from training and testing are growing in the same order, efficient value function estimates can deliver competitive performance. We further show some connections of these estimates with existing literature. However, when the growth of testing sample size available for training is in a slower order, efficient value function estimates may not perform well anymore. In contrast, the requirement of the testing sample size for DRITR is not as strong as that of efficient policy evaluation using the combined data. Finally, we highlight the general applicability and usefulness of DRITR in Section 3.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.